Back to Cell Types

HuCC-T1Homo sapiens (Human)Cancer cell line

Also known as: HuCCT1, HUCCT1, HUCC-T1, HUCCT-1, HuCCT-1

🤖 AI SummaryBased on 10 publications

Quick Overview

Human cholangiocarcinoma cell line with tumor marker secretion capabilities.

Detailed Summary

HuCC-T1 is a human cholangiocarcinoma cell line established from the ascites of a 56-year-old male patient. It exhibits epithelial-like morphology and secretes multiple tumor markers, including carbohydrate antigen 19/9 (CA19/9), which is a key biomarker for cholangiocarcinoma. The cell line is tumorigenic in nude mice and has been maintained for over 51 passages. It shows distinct growth characteristics in serum-free medium, with high CA19/9 secretion levels. The cell line provides a valuable model for studying tumor marker secretion and cholangiocarcinoma biology.

Research Applications

Tumor marker secretion studiesCholangiocarcinoma biologyIn vitro drug testingCell line development

Key Characteristics

Secretes CA19/9, CEA, CA125, and TPATumorigenic in nude miceMaintained in serum-free mediumEpithelial-like morphologyHigh CA19/9 secretion in 1% FBS medium

Generated on 6/15/2025

Basic Information

Database ID	CVCL_0324
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age	56
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Cholangiocarcinoma
Lineage	Biliary Tract
Subtype	Intrahepatic Cholangiocarcinoma
OncoTree Code	IHCH

DepMap Information

Source Type	HSRRB
Source ID	ACH-000976_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg175His (c.524G>A)	Unspecified	Somatic mutation acquired during proliferation	from parent cell line YCC-3
MutationSimple	MSH6	p.Lys1358fs*2 (c.4071_4072insGATT)	Heterozygous	-	Unknown, Unknown
MutationSimple	KRAS	p.Gly12Asp (c.35G>A)	Unspecified	-	PubMed=29786757

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

11,12

D12S391

18,20

D13S317

11,13

D16S539

9,11,12

D18S51

13

D19S433

13

D21S11

31

D2S1338

17,18

D3S1358

15

D5S818

12,13

D6S1043

13

D7S820

10,11

D8S1179

10

FGA

20,23

Penta D

10

Penta E

15,18

TH01

7,10

TPOX

8

vWA

18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.

Vazquez F., Getz G., Bardeesy N.M.

bioRxiv 2024:07.04.601970-07.04.601970(2024).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Development and characterization of human primary cholangiocarcinoma cell lines.

Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.

Am. J. Pathol. 192:1200-1217(2022).

RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.

Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.

Cancers (Basel) 12:2510.1-2510.14(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Jirawatnotai S.

Hepatology 70:1614-1630(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.

Bardeesy N.M.

Cancer Discov. 6:727-739(2016).

Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.

Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.

Oncotarget 7:20080-20092(2016).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.

Kosaka K., Chayama K.

Int. J. Oncol. 39:561-568(2011).

Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.

Tsuchiya T., Gotoh M.

J. Hepatobiliary Pancreat. Sci. 18:700-711(2011).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.

Miyagiwa M., Ichida T., Tokiwa T., Sato J., Sasaki H.

In Vitro Cell. Dev. Biol. 25:503-510(1989).

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Ohashi R., Namba M.

Tissue Cult. Res. Commun. 16:173-178(1997).